Received Sep 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
Nose bleed; This non-serious case was reported by a consumer via call center representative and described the occurrence of epistaxis in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On 21-AUG-2025, the patient received the 1st dose of Shingles vaccine. On 21-AUG-2025, 4 hrs after receiving Shingles vaccine, the patient experienced epistaxis (Verbatim: Nose bleed). The outcome of the epistaxis was not reported. It was unknown if the reporter considered the epistaxis to be related to Shingles vaccine. It was unknown if the company considered the epistaxis to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 21-AUG-2025 The patient got the first dose of vaccine that day (the day of reporting), and got a nose bleed 4 hours later. The patient rarely ever got nose bleeds. The patient wanted to know if that could be from the vaccine.